全球鐮狀細胞疾病（SCD）治療市場規模、佔有率、趨勢和成長分析報告：2026-2034年

預計鐮狀細胞疾病 (SCD) 治療市場規模將從 2025 年的 46.5 億美元成長到 2034 年的 224.8 億美元，2026 年至 2034 年的複合年成長率為 19.12%。

由於全球對鐮狀細胞疾病 (SCD) 的認知不斷提高以及診斷率的提升，SCD 治療市場正在不斷擴大。傳統的治療方法主要包括止痛和輸血，而如今，治療方法已發展到包括使用緩解疾病藥物和先進的生物製藥。研發投入的增加以及孤兒藥的優先資助正在加速創新，尤其是在基因治療和根治性療法領域。

關鍵成長要素包括特定地區發病率上升、新生兒篩檢計畫改善以及針對罕見疾病的有利法規結構。基因編輯技術和造血幹細胞移植的進步正在開闢新的治療途徑。製藥公司正投資研發標靶治療減輕閉塞性疾病危機並提高患者的生活品質。

基因療法商業化帶來的治癒性治療潛力使其未來前景十分光明。然而，高昂的治療費用和醫療資源分配不均可能阻礙其廣泛應用。為了在未來幾年實現持續成長，新興市場醫療基礎設施的擴建和醫保報銷的加強至關重要。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球鐮狀細胞疾病（SCD）治療市場：依藥物類別分類

• 市場分析、洞察與預測
• 抗代謝藥物
• 胺基酸
• NSAIDs
• 單株抗體
• 其他（止痛藥、退燒藥等）

第5章 全球鐮狀細胞疾病（SCD）治療市場：依疾病類型分類

• 市場分析、洞察與預測
• 血紅素SS（HbSS）
• SC血紅素（HbSC）
• BETA-地中海型貧血血紅蛋白（HbS）

第6章 全球鐮狀細胞疾病（SCD）治療市場：依年齡層分類

• 市場分析、洞察與預測
• 孩子
• 成人

第7章 全球鐮狀細胞疾病（SCD）治療市場：依給藥途徑分類

• 市場分析、洞察與預測
• 口服
• 腸外

第8章 全球鐮狀細胞疾病 (SCD) 治療市場：依分銷管道分類

• 市場分析、洞察與預測
• 醫院藥房
• 零售藥房
• 網路藥房

第9章 全球鐮狀細胞疾病（SCD）治療市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第10章 競爭格局

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第11章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Novartis AG
  • Pfizer Inc
  • Bristol-Myers Squibb Company
  • CRISPR Therapeutics
  • Emmaus MedicalInc
  • Bluebird BioInc
  • Hoffmann-La Roche Ltd
  • Vertex Pharmaceuticals Incorporated
  • Agios PharmaceuticalsInc
  • GlycoMimetics
  • Graphite BioInc
  • Mylan NV
  • Teva Pharmaceutical Industries Ltd
  • AstraZeneca
  • Hikma Pharmaceuticals PLC

The Sickle Cell Disease Treatment Market size is expected to reach USD 22.48 Billion in 2034 from USD 4.65 Billion (2025) growing at a CAGR of 19.12% during 2026-2034.

The sickle cell disease (SCD) treatment market has expanded as awareness and diagnosis rates improve globally. Traditionally managed with pain-relief therapies and blood transfusions, treatment approaches have evolved to include disease-modifying drugs and advanced biologics. Increasing research investment and orphan drug incentives have accelerated innovation, particularly in gene therapy and curative approaches.

Major growth drivers include rising prevalence in certain geographic regions, improved newborn screening programs, and supportive regulatory frameworks for rare diseases. Advances in gene-editing technologies and hematopoietic stem cell transplantation have opened new therapeutic possibilities. Pharmaceutical companies are investing in targeted therapies that reduce vaso-occlusive crises and improve patient quality of life.

Future prospects are highly promising with the commercialization of gene therapies offering potential long-term cures. However, high treatment costs and access disparities may challenge widespread adoption. Expanding healthcare infrastructure and reimbursement support in emerging markets will be crucial for sustainable growth in the coming years.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Class

• Antimetabolites
• AminAcids
• NSAIDs
• Monoclonal Antibodies
• Others (Analgesis and Antipyretics, etc)

By Disease Type

• Hemoglobin S5 (HbSS)
• Hemoglobin SC (HbSC)
• Hemoglobin (HbS) beta thalassemia

By Age-Group

• Children
• Adults

By Route of Administration

• Oral
• Parenteral

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• Novartis AG, Pfizer Inc, BristolMyers Squibb Company, CRISPR Therapeutics, Emmaus Medical, Inc, Bluebird Bio, Inc, HoffmannLa Roche Ltd, Vertex Pharmaceuticals Incorporated, Agios Pharmaceuticals, Inc, GlycoMimetics, Graphite Bio, Inc, Mylan NV, Teva Pharmaceutical Industries Ltd, AstraZeneca, Hikma Pharmaceuticals PLC

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Class
• 4.2. Antimetabolites Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. AminAcids Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. NSAIDs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Monoclonal Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Others (Analgesis and Antipyretics, etc) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET: BY DISEASE TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Disease Type
• 5.2. Hemoglobin S5 (HbSS) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Hemoglobin SC (HbSC) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Hemoglobin (HbS) beta thalassemia Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET: BY AGE-GROUP 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Age-group
• 6.2. Children Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Adults Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Route Of Administration
• 7.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Parenteral Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Distribution Channel
• 8.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET: BY REGION 2022-2034(USD MN)

• 9.1. Regional Outlook
• 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.2.1 By Drug Class
  • 9.2.2 By Disease Type
  • 9.2.3 By Age-group
  • 9.2.4 By Route Of Administration
  • 9.2.5 By Distribution Channel
  • 9.2.6 United States
  • 9.2.7 Canada
  • 9.2.8 Mexico
• 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.3.1 By Drug Class
  • 9.3.2 By Disease Type
  • 9.3.3 By Age-group
  • 9.3.4 By Route Of Administration
  • 9.3.5 By Distribution Channel
  • 9.3.6 United Kingdom
  • 9.3.7 France
  • 9.3.8 Germany
  • 9.3.9 Italy
  • 9.3.10 Russia
  • 9.3.11 Rest Of Europe
• 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.4.1 By Drug Class
  • 9.4.2 By Disease Type
  • 9.4.3 By Age-group
  • 9.4.4 By Route Of Administration
  • 9.4.5 By Distribution Channel
  • 9.4.6 India
  • 9.4.7 Japan
  • 9.4.8 South Korea
  • 9.4.9 Australia
  • 9.4.10 South East Asia
  • 9.4.11 Rest Of Asia Pacific
• 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.5.1 By Drug Class
  • 9.5.2 By Disease Type
  • 9.5.3 By Age-group
  • 9.5.4 By Route Of Administration
  • 9.5.5 By Distribution Channel
  • 9.5.6 Brazil
  • 9.5.7 Argentina
  • 9.5.8 Peru
  • 9.5.9 Chile
  • 9.5.10 South East Asia
  • 9.5.11 Rest of Latin America
• 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.6.1 By Drug Class
  • 9.6.2 By Disease Type
  • 9.6.3 By Age-group
  • 9.6.4 By Route Of Administration
  • 9.6.5 By Distribution Channel
  • 9.6.6 Saudi Arabia
  • 9.6.7 UAE
  • 9.6.8 Israel
  • 9.6.9 South Africa
  • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

• 10.1. Recent Developments
• 10.2. Company Categorization
• 10.3. Supply Chain & Channel Partners (based on availability)
• 10.4. Market Share & Positioning Analysis (based on availability)
• 10.5. Vendor Landscape (based on availability)
• 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL SICKLE CELL DISEASE TREATMENT INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Company Profiles
  • 11.2.1 Novartis AG
  • 11.2.2 Pfizer Inc
  • 11.2.3 Bristol-Myers Squibb Company
  • 11.2.4 CRISPR Therapeutics
  • 11.2.5 Emmaus MedicalInc
  • 11.2.6 Bluebird BioInc
  • 11.2.7 Hoffmann-La Roche Ltd
  • 11.2.8 Vertex Pharmaceuticals Incorporated
  • 11.2.9 Agios PharmaceuticalsInc
  • 11.2.10 GlycoMimetics
  • 11.2.11 Graphite BioInc
  • 11.2.12 Mylan N.V
  • 11.2.13 Teva Pharmaceutical Industries Ltd
  • 11.2.14 AstraZeneca
  • 11.2.15 Hikma Pharmaceuticals PLC